A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

Trial Profile

A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Dianhydrogalactitol (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms REPROVe
  • Sponsors DelMar Pharmaceuticals
  • Most Recent Events

    • 18 Sep 2017 According to DelMar Pharmaceuticals media release, DelMar anticipates opening the VAL-083 REPROVe Trial for patient enrollment in early 2018.
    • 18 Sep 2017 According to DelMar Pharmaceuticals media release, this trial has received IND Allowance from FDA.
    • 18 Sep 2017 According to DelMar Pharmaceuticals media release, 24 patients will be enrolled under the first phase of the VAL-083 REPROVe Trial with top line results expected within 18-24 months from trial initiation of patient treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top